SLNO - Soleno Therapeutics Inc
IEX Last Trade
48.99
2.425 4.950%
Share volume: 475,543
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$46.56
2.43
5.21%
Fundamental analysis
11%
Profitability
0%
Dept financing
14%
Liquidity
58%
Performance
10%
Performance
5 Days
8.18%
1 Month
4.91%
3 Months
14.83%
6 Months
-3.07%
1 Year
857.93%
2 Year
2,155.76%
Key data
Stock price
$48.99
DAY RANGE
N/A - $49.15
52 WEEK RANGE
$3.69 - $53.82
52 WEEK CHANGE
$8.83
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Anish Bhatnagar
Region: US
Website: http://www.capnia.com/
Employees: 27
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.capnia.com/
Employees: 27
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
Recent news